drugset / Trial / NCT00702325

Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans

NCT00702325

Phase 4 Completed 311 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the efficacy of SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily (bid) to that of budesonide inhalation powder DPI 180 μg x 2 inhalations bid, in African American(self-reported) subjects with inhaled corticosteroid (ICS) dependent asthma.

Timeline

Start
2008-06
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 160 ug Inhaled
Comparator Budesonide Small molecule 180 ug Inhaled
Subject Formoterol Other / unclassified 4.5 ug Inhaled

Indications